| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0611 |
| Trial ID | ChiCTR2000031868 |
| Disease | B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Generation | 2nd |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor Engineered T cells in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma |
| Year | 2020 |
| Country | China |
| Company sponsor | The First Affiliated Hospital of USTC (Anhui Provincial Hospital) |
| Cohort 1 | |||||||||||||||
|
|||||||||||||||